HORIZON 2020 The EU Framework Programme for Research and Innovation OVERVIEW OF RESEARCH ACTIVITIES IN INFECTIOUS DISEASES OCTA - European Parliament 20th October 2015 Inmaculada Peñas Jiménez 'Fighting Infectious Diseases and Global Epidemics DG Research & Innovation European Commission 1
28
Embed
HORIZON 2020 The EU Framework Programme for Research and Innovation OVERVIEW OF RESEARCH ACTIVITIES IN INFECTIOUS DISEASES OCTA - European Parliament 20th.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
HORIZON 2020The EU Framework Programme for Research and Innovation
OVERVIEW OF RESEARCH ACTIVITIES IN INFECTIOUS DISEASES
OCTA - European Parliament 20th October 2015
Inmaculada Peñas Jiménez
'Fighting Infectious Diseases and Global Epidemics
DG Research & InnovationEuropean Commission 1
The role of the European Commission - Research and innovation
Develop and implement the European research and innovation policy agreed by the European Parliament and European Council.
Funds research through multi-annual framework programmes for research (since 1984). Implemented through annual work programmes and call for proposals and independent peer review of proposals.
The European Commission manages about 5% of total public spending in R&D in the European Union.
2
Key priorities for infectious diseases in the Health, Demographic Change and Wellbeing
Theme
• Emerging infectious diseases (EE)Influenza and other emerging diseases (incl vector-borne diseases)
Some figures of the researchin major infectious diseases
funded by the FP7 (2007-2013)
4
Some FP7 projects…
• IDAMS € 6 million EU contribution - Start 01/09/2011 - 60 months• Is improving clinical and laboratory diagnosis and clinical management of dengue;
identifying markers to differentiate dengue from other febrile illness; likelihood to evolve to a more severe disease; risk of dengue spread and maps; and developing effective and affordable early warning systems and outbreak responses
• 18 participants from 14 countries including from Mexico,Malaysia and Ghana
• DENGUETOOLS € 6 million EU contribution - Start 01/09/2011 - 54 months• Developing early diagnostic tests, laboratory-based early warning systems, predictive
models and risk maps better surveillance as well as developing a community-based strategy to reduce dengue incidence in school aged children
• 15 participants from 11 countries including Brasil, Sri Lanka and Singapore
• DENFREE € 6 million EU contribution - Start 01/01/2012 - 60 months• Is identifying the key factors determining transmission, outcome of infection and
epidemics of dengue fever, as well as developing of novel diagnostic tools to detect asymptomatic infections, and estimating the risk of virus spreading to uninfected areas
• 15 participants from 11 countries including Cuba, Cambodia and French Polynesia
5
What is Horizon 2020?
− Responding to the economic crisis to invest in future jobs and growth
− Addressing people’s concerns about their livelihoods, safety and environment
− Strengthening the EU’s global position in research, innovation and technology
6http://ec.europa.eu/research/horizon2020
The EU’s 2014-20 programmefor research & innovation
A core part of Europe 2020, Innovation Union &European Research Area
•Excellent science
•Industrial leadership
•Societal challenges
• European Research Council• Future and Emerging Technologies• Marie Skłodowska-Curie actions• Research infrastructures
• Leadership in enabling and industrial technologies
• Access to risk finance
• Innovation in SMEs
SC1- Health, demographic changes
and wellbeing (€ 7.5 b)
The new EU programme for research and innovation € 79 billion (2014-2020)
HORIZON 2020 (2014-2020)
Collaborative projects
SME instrument
Financial instruments
Eureka Eurostars-2
AAL-2IMI-2
SC1 Health €7.5bn (of €31bn)
Industrial leadership €17bn
Excellent science €24bn
Health in H2020Future and Emerging
Technologies
LEIT Biotech
Marie Skłodowska Curie
Fast Track to Innovation
EDCTP-2
European Research Council
Research Infrastructures
8
Infectious Diseases R&I – Collaboration for innovative solutions – Implementation
1 – Collaborative research projects
Implemented by DG RTD
2 - Horizon prize
Implemented by DG RTD
3 – Global Initiatives
GLOPID- R ; GTBVP; World RePORT
4- Public–Private partnership
IMI2: From discovery to human testing to regulatory aspects, HTA and pharmacovigilence
5- Public–Public partnership
EDCTP2
Joint Programme on AMR
ERA-INFECT
6- Infectious Disease Finance Facility – INNOVFIN ID
jointly developed by EC and EIB 9
Infectious diseases in Horizon 2020 COLLABORATIVE RESEARCH
Priorities addressed in 2014-2015:
• Vaccine development for poverty related and neglected infectious diseases• 2014 – Tuberculosis € 25 million – 2 projects funded • 2015 – HIV/AIDS € 45 million – 2 projects funded
• 2014 – COMPARE - Development of web based system for rapid identification, containment and mitigation of emerging infectious diseases and foodborne outbreaks by generation and comparison of genomic information on samples and pathogens across sectors, time and locations, with contextual additional data.
• 2014 - I-MOVE+,a scientific public health platform to identify, pilot test, use and disseminate the best study designs to measure the effectivenes (direct effect)and the impact (indirect and overall effect) of influenza and pneumococcal vaccines
10
The challenges
• Ageing population
• Increased disease burden
• Unsustainable and unequal health & care systems
• Health & care sector under pressure to reform
11
Who's eligible for funding?• Horizon 2020 is open to participation from across the
world
• By default:
• Member States (including overseas departments and overseas territories)
• Associated Countries
• exhaustive list of countries in annex to workprogramme (but: no longer BRIC + Mexico in this list!)
• Participants from other countries are funded inexceptional cases:
• when provision is made in the call text
• bilateral agreement (e.g. USA, Health challenge – NIH)
• when the Commission deems it essential (case by case assessment)
12
Methods and data
Health care provision and integrated care
Active ageing and self-management of health
Treating and managing diseases
Preventing disease
Understanding health, well-being & disease
The Horizon 2020 Health Challenge:WP 2016-2017
'Personalised Medicine'
'coordination activities'
ERA-NETs , Joint Programming, Global Alliance for Chronic Diseases (GACD), Valorisation of FP7 results and other Coordination Actions
€ 930million13
Understanding the call topics: example
• 'PHC 2 – 2015'
• 'Specific challenge'
• 'Scope'
• 'Expected impact'
• 'Type of action'
14
Topics 2016-2017 - 1.1 Understanding health, well-being and disease:
• PM 01 – 2016 – Multi omics for personalised therapies [RTD]
• PM 02 – 2017- New concepts in patient stratification [RTD]
• HCO 16- 2016 – Standardisation needs in the field of ICT for Active and Healthy Ageing [CNECT]
21
HORIZON PRIZE• The European Commission has launched the:
Horizon Prize for Better use of Antibiotics
• This challenge prize is offering a cash reward of
€1 million• To the person or team who can most effectively meet the following
challenge: Develop a rapid test that will allow healthcare providers to distinguish, at the point-of-care, between patients with upper respiratory tract infections that require antibiotics and those that can be treated safely without them
Upper Respiratory Tract Infections include pharyngitis, sinusitis, otitis and bronchitis
22
GLOPID-R A Global Research Collaboration for
Infectious Disease Preparedness
• A global multifunder initiative
• A network of research funders which aims to spark a collaborative global research response within 48 hours, after an outbreak
• Key funders from Australia, Brazil, Canada, China, South Africa, US, France, UK, Sweden, Spain, Germany
23
Facilitate exchange of information
Address scientific, legal, ethical and financial challenges
Implement a 'One Health' approach with close cooperation between human and animal health researchers
Establish a strategic agenda for research response
Connect infectious disease research networks
Create partnerships with low-income countries24
GloPID-R objectives
EDCTP2 (2014 – 2024)• Broader scope: support to clinical trials to bring
treatments, vaccines, diagnostics and delivery optimisation closer to the patients of HIV/AIDS, TB, malaria and neglected infectious diseases
• More EU co-funding€683 million from EU Horizon2020 + at least the same amount from participating countries
• Governance 28 full member countries: 14 African + 14 European countries
• Publication of work plan 2015http://www.edctp.org
25
26
Diseases: HIV/AIDS, TB, Malaria, NIDs, emerging infectious diseases of particular relevance for Africa, including Ebola
New tools and interventions: Diagnostics, drugs, vaccines and microbicides
General rules for participation: At least 2 legal entity in EU Member States or in countries associated to Horizon 2020 and one legal entity in Sub Saharan Africa
Get prepared!
Free of charge services to assist you:
•Call text, guide for applicants, FAQs: Participant portalhttp://ec.europa.eu/research/participants/portal/desktop/en/home.html
•Practical information & assistance: National Contact Points (NCPs), Enterprise Europe Network (EEN)